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Dynamic contrast-enhanced (albumin-Gd-DTPA) magnetic resonance imaging, performed during 2 weeks of daily administration of
an inhibitor of tyrosine kinase receptors (SU6668) in an HT-29 colon carcinoma model, revealed the onset of a hyper-enhancing rim,
not observed in untreated tumours. To account for tissue heterogeneity in the quantitative analysis, we segmented tumours into
three subunits automatically identified by cluster analysis of the enhancement curves using a k-means algorithm. Transendothelial
permeability (Kps) and fractional plasma volume (fPV) were calculated in each subunit. An avascular and necrotic region, an
intermediate zone and a well-vascularised periphery were reliably identified. During untreated tumour growth, the identified sub-
regions did not substantially change their enhancement pattern. Treatment with SU6668 induced major changes at tumour periphery
where a significant increase of Kps and fPV was observed with respect to control tumours. Histology revealed a sub-capsular layer
composed of hyper-dense viable tumour cells in the periphery of untreated tumours. The rim of viable neoplastic cells was reduced in
treated tumours, and replaced by loose connective tissue characterised by numerous vessels, which explains the observed hyper-
enhancement. The present data show a peripheral abnormal development of cancer-associated stroma, indicative of an adaptive
response to anti-angiogenic treatment.
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Tumours possess an extraordinary plasticity that enables them to
adapt to drastic microenvironmental changes; this leads to the
undesirable development of therapy resistance, recurrence and
metastatic process. In recent years, epithelial–stromal interaction
in carcinomas is emerging as a crucial factor, which could be
involved in their adaptive plasticity (Liotta and Kohn, 2001;
Mueller and Fusenig, 2004). For example, the evolution of
mammary carcinomas towards a mesenchymal phenotype in mice
has been shown to be a common consequence of specific immune
attack (Knutson et al, 2006) and drug-based treatment (Knutson
et al, 2004). Furthermore, the spontaneous development of
mesenchymal tumour after regression of the epithelial compart-
ment has been proposed as a model of tumour recurrence (Moody
et al, 2005).
The development of resistance to anti-angiogenic therapies is a
clinically important paradigm of tumour plasticity. Clinical studies
over the past two decades have demonstrated that treatment with
tyrosine kinase pathway inhibitors results in a fleeting period of
clinical benefit, after which the disease restart to progress. Four
distinct adaptive mechanisms are currently thought to be at the
basis of the transitory effects of anti-angiogenic drug (Casanovas
et al, 2005; Bergers and Hanahan, 2008): (1) activation of
alternative pro-angiogenic signaling pathways, (2) recruitment of
bone-marrow-derived endothelial and blood precursors, (3)
increased perycite coverage of the tumour vasculature and (4)
invasion and metastasis of surrounding or distant tissues.
In the present study we provide evidence of an additional
mechanism, that is the development of an aberrant vascular
supporting stroma at tumour periphery, following a prolonged
anti-angiogenic treatment. For this purpose, we performed a time
evolution study in an experimental colon carcinoma model
by dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) to assess tumour vascular responses during 2 weeks
of treatment with SU6668, a small molecule inhibitor of the
angiogenic receptor tyrosine kinases, VEGFR-2 (Flk-1/KDR),
PDGFR-b and FGFR1.
MATERIALS AND METHODS
The investigation complied with national legislation about the care
and use of laboratory animals.
HT-29 human colon carcinoma fragments were implanted s.c. in
the flanks of 12 athymic nu/nu mice. Treated animals (n¼7)
underwent daily administration of SU6668 (200mgkg
 1 per day,
p.o.) for 14 days; control animals (n¼5) received Cremophor-
based vehicle. SU6668, a small molecule multi-tyrosine kinase
inhibitor, is an analogue of sunitinib, developed in Sugen (La Jolla,
CA, USA) and then clinically discontinued because sunitinib was
preferred due to a better response.
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was performed at days 0, 7 and 14 on both treated and untreated
animals. Gd-DTPA-albumin was used as contrast agent according
to the protocol described in Marzola et al (2004). Three-dimen-
sional transversal spoiled-gradient echo images were acquired with
the following parameters: TR/TE¼50/3.5ms, flip angle¼901,
matrix size 128 64 32, field of view 5 2.5 3cm
3. The
acquisition time for a single scan was 104s; a dynamic scan of
24 images was acquired with 30-s time intervals between each
image (total acquisition time 53min). The 30-s time interval
allowed to avoid overheating of the gradient insert. Pre-contrast T1
values were measured using an inversion recovery snapshot Flash
technique. The contrast agent was injected in bolus during the time
between the first and the second scan. The plasma kinetics of
contrast medium was determined ex vivo. From DCE-MRI data,
transendothelial permeability (Kps) and fractional plasma volume
(fPV) were calculated on a pixel-by-pixel basis as in Demsar et al
(1997). To obtain mixed fPV/Kps images in red-green-blue format
as in Bhujwalla et al (2001), fPV values were assigned to red
intensities, and Kps values to green intensities.
To provide quantitative analysis taking into account of tumour
heterogeneity, an automated operator-independent method, based
on cluster analysis, was developed to identify sub-regions inside
the tumour. A volume of interest (VOI) was manually drawn to
cover the whole tumour. Each VOI was then segmented into three
different compartments by applying a k-means cluster algorithm
(implemented in Matlab; MathWorks, Natick, MA, USA) to the
enhancement curves, Enh(t), defined by:
EnhðtÞ¼ð SIðtÞ SIð0ÞÞ=SIð0Þ
where SI(t) and SI(0) are the signal intensity values at time t and 0
respectively. The L1 metric (defined as L1(x, y)¼Si |xi yi| for
vectors x and y) was selected as the ‘distance’ function for
all partitioning steps of the clustering algorithm. Although both
from MRI and from histological examination two main tumour
compartments were identified (an avascular core and a well-
vascularised periphery), a third cluster was considered in the
k-means clusterisation algorithm, to take into account pixels having
intermediate vascularisation and/or possible partial volume effects.
For each of the three identified subunits mean Kps, fPV and
volume were calculated; for the whole VOI mean and Kps and fPV
were calculated. Non-parametric test (Wilcoxon) was then applied
on the obtained values to statistically compare treated and
untreated tumours.
At day 14 mice were killed and their tumours were excised for
histological examination. Two animals belonging to the treated
group were killed at day 7. After fixation in zinc fixative for 6h,
tumours were cut in half on a plane corresponding to that used for
the MR images. After embedding in paraffin, 5mm thick slices were
cut and stained with H&E.
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Figure 2 Mixed images: drug effect vs controls. Representative mixed images of untreated tumour growth at day 0 (A), day 7 (B) and day 14 (C) and of
treatment progression at day 0 (D), day 7 (E) and day 14 (F).
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Figure 1 MRI mixed images. An fPV map in red (A) and Kps map in
green (B) were mixed to produce the image (C) by the corresponding
colour scale (D). Yellow pixels in the mixed images indicate high fPV and
high Kps. In (A) white dotted lines represent a manually drawn region
encompassing the whole tumour. The central section of the tumour is
shown, and the heart is visible left of the tumour (*).
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sRESULTS
MRI analysis
The combined fPV/Kps maps clearly showed the architecture of
tumour vasculature (Figures 1 and 2). Tumour periphery was
characterised by high fPV (red), whereas tumour core had low fPV
but detectable Kps (green). The different pattern between the
periphery and the core was observed in all untreated tumours and
was preserved during their growth. During SU6668 treatment,
marked changes in vasculature were clearly identifiable at the
tumour periphery, with the appearance of a layer of yellow pixels
(high fPV and high Kps). These unexpected peripheral findings
were observed in about 70% (five out of seven) of the treated
tumours.
Cluster analysis allowed identification of sub-regions inside the
tumour (Figure 3), with a peripheral well-enhanced sub-region
clearly identified. Full data on all three identified subunits are
reported in Figure 4. The balance between the volumes of the three
subunits resulted relatively stable during both untreated tumour
growth (when there was an increase in total tumour volume) and
anti-angiogenic administration (when there was a limited increase
in total tumour volume). The most evident changes induced by
SU6668 occurred in the peripheral sub-region characterised by
higher vascular parameters with respect to the semi-necrotic and
avascular zones. In this peripheral subunit, the progression in
untreated tumour revealed a reduction in Kps; on the contrary in
the treated tumours an increase was observed comparing day 7
with the pre-treatment point. In particular, Kps and fPV values
were significantly higher (Po0.05) after 7 days of therapy than the
values obtained in the corresponding control tumours (Table 1).
The same table showed that mean values for the whole tumour VOI
were not significantly different. At day 14 the higher Kps and fPV
values in the treated tumours with respect to controls were not
significant at a 0.05 level, because the MRI examination was
performed only on three of the five mice that showed hyper-
enhancement at day 7.
Histological examination
In untreated tumours the peripheral zone, which surrounds central
semi-necrotic areas, proved to be densely populated by viable
neoplastic cells (Figure 5A–C). After 7–14 days of treatment
(Figure 5D–F), the capsular connective tissue and the enlarged
vessels, contiguous to the layer of viable tumour, were similar to
those observed in control samples. However, SU6668 induced a
decrease in viable tumour cells at the tumour periphery. The
tumour cells were replaced by an increased amount of loose
connective tissue, characterised by numerous small vessels, which
presumably was responsible for the peripheral hyper-enhancement
observed by DCE-MRI.
DISCUSSION
Dynamic contrast-enhanced magnetic resonance imaging is now
being used as an in vivo biomarker to evaluate the efficacy of
Table 1 VOI kinetic parameters
Day 0 Day 7 Day 14
Whole tumour VOI
Kps 10
 5 (mean)
Controls 5.3±1.2 4.1±1.6 4.4±0.6
Treated 4.7±1.1 5.9±1.4 3.7±0.3
fPV 10
 3 (mean)
Controls 1.9±0.7 1.9±1.1 1.2±0.3
Treated 3.1±1.2 2.7±0.7 2.7±1.4
Peripheral sub-region
Kps 10
 5 (mean)
Controls 11.3±3.5 6.5±2.8* 6.2±1.1
Treated 10.4±4.0 15.8±6.5* 9.9±4.7
fPV 10
 3 (mean)
Controls 6.7±0.8 6.9±2.6* 8.2±2.4
Treated 8.7±2.6 10.9±1.8* 9.9±5.7
% Vol. (mean)
Controls 13.4±3.2 15.6±5.2 12.4±1.5
Treated 16.2±2.1 14.1±2.6 15.0±3.7
VOI¼volume of interest; Kps¼transendothelial permeability; fPV¼fractional
plasma volume. Mean Kps (mlmin
 1cm
 3) and fPV (mlcm
 3) values obtained on
the whole tumour VOI and the peripheral sub-region segmented by cluster analysis
and obtained averaging on the whole tumour groups. The mean percentage volumes
of the peripheral sub-region are also reported. The asterisk (*) indicates a significant
(at a 0.05 level) difference in the comparison between treated and controls. Data
were obtained on n¼5 control and n¼7 treated tumours, but at day 14 only 5 of
the 7 treated tumours were examined by DCE-MRI.
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Figure 3 Cluster analysis automatically identifies sub-regions inside the
tumour. Representative results obtained at 7 and 14 days in a control (A)
and in a treated case (B) are shown. An avascular region (green), an
intermediate (red) and a well-vascularised area (cyan) are identifiable. The
time–course of their normalised signal enhancement is shown with the
respective color identification below each picture. Number of scans is
reported in abscissa. During untreated tumour growth, the identified sub-
regions did not substantially change their enhancement pattern, whereas
the most marked difference between untreated and treated tumours was
observed in the peripheral sub-region.
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2005; O’Connor et al, 2007). The potential of DCE-MRI to evaluate
intra-tumoural heterogeneity and investigate its relationship with
response to therapy was recently emphasised (Jackson et al, 2007).
One approach to investigate heterogeneity is based on histogram
analysis of the distribution of pharmacokinetic parameters inside
the tumour, which allows to demonstrate a rim–core difference in
drug effect (Checkley et al, 2003). To overcome the limitation of
the analysis of distribution based on a single or a small number of
summary parameters, statistical techniques like principal compo-
nent analysis (PCA) have been proposed (O’Connor et al, 2005).
Alternatively, clusterisation algorithms like k-means, closely
related to PCA (Ding and He, 2004), can be used to obtain
unsupervised and automatic VOI segmentation to account for
tumour heterogeneity.
To develop an approach independent from any pharmaco-
kinetics model, we have directly analysed the enhancement curves
instead of using calculated Kps/fPV values. However, as the
scanner gain could change between examinations, the signal
intensity values were normalised to pre-contrast values. The
successive evaluation of pharmacokinetic parameters on the
obtained clusters, and in particular on the peripheral sub-region,
proved to be more sensitive to the alteration induced by anti-
angiogenic therapy than the analysis performed on the whole
tumour VOI. Our results raise the hypothesis that cancer-
associated stroma is involved in the ability of carcinomas to adapt
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Figure 4 Summary of volumes and vascular parameters in the whole experiment. Volume (A and B), mean enhancement (C and D), Kps (E and F) and
fPV (G and H) data on the three subunits identified by clustering algorithm, obtained by averaging data from different mice (controls, on the left; treated, on
the right) at days 0, 7 and 14. Mean enhancement was taken as the mean value on the normalised enhancement curve. Error bars represent standard
deviations across the group of tumours. The three identified sub-regions correspond to avascular (green), intermediate (red) and vascularised (cyan) areas.
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sto anti-angiogenic therapy. Prolonged SU6668 administration
promoted abnormal development of the stromal compartment at
the periphery of the treated tumours: this rim appeared
significantly more perfused with respect to control tumours,
consistently with the well-recognised role of stroma in tumour
vasculature organisation. Our findings may suggest a different and
more comprehensive mechanism of resistance to anti-angiogenic
therapies, which encompasses those already described by Bergers
and Hanahan (2008). In fact, an aberrant development of tumour
stromal cells, including perycites, is often associated with
increased release of pro-angiogenic factors, increased recruitment
of bone-marrow-derived endothelial and blood precursors, and
invasion and metastasis to surrounding tissues.
The observations at days 7 and 14 complement previous
findings (Marzola et al, 2004), where the ‘standard’ effect of
anti-angiogenic drugs, namely a decrease in peripheral Kps and
fPV, was observed in treated tumours at early time points (24h to
3 days of treatment). Because anti-angiogenics cannot be expected
to function as effective tumour therapy on their own, regimens
combining them with chemo-irradiation are essential for local
tumour treatment (Timke et al, 2008). Anti-angiogenics induce
pathophysiologic changes that can have a positive influence on
tumour response to more conventional therapies (Horsman and
Siemann, 2006). The appearance of an efficient vasculature and the
decrease in tumour cell density, observed at the tumour periphery
after prolonged SU6668 administration, could increase the
sensitivity of this part of the tumour to a subsequent chemo-
irradiation. On the other hand, this unexpected stromal reaction
might potentially lead to an overall increase in tumour aggres-
siveness. Because of the termination of clinical development of
SU6668 (Xiong et al, 2004), few data are available to verify the
development of an abnormal cancer-associated stroma in human
studies. However, this could be investigated with other anti-
angiogenic compounds. If the described effect is confirmed in
clinical research, its influence on chemo-irradiation will need to be
elucidated, and should be taken into account for optimal
scheduling of the combination regimen.
ACKNOWLEDGEMENTS
This work was partially supported by the Fondazione Cassa di
Risparmio di Verona, Vicenza, Belluno e Ancona; project:
Integrated Unit of Multimodal Molecular Imaging.
AD
BE
CF
Figure 5 H&E histology at day 14. Histological sections from a control (A–C) and a treated (D–F) tumour. In the control case, the whole section
revealed the presence of a peripheral zone with viable tumour cells showing nested intrusion into the contiguous semi-necrotic areas (A). Inside this matrix
of viable cells, some vessels were detectable, which were particularly enlarged at the interface with tumour capsule, in a zone immediately contiguous (but
external) to viable tumour tissue (B). At high magnification (C), the tumour cells appeared mixed with loose connective tissue. After 7–14 days of
treatment, a marked decrease in the thickness of viable peripheral layer was clearly detectable all around the external tumour border (D). In the peripheral
layer, the viable tumour cells appeared almost completely replaced by an increased amount of loose connective tissue (E), characterised by numerous
vessels (F). Scale bar, 1.5mm (A and B), 125mm( C), 60mm( D), 10mm( E and F).
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